Anuh Pharma Q2 FY2027 Net Profit Rises 47%

Date: 30th October, 2026

Revenue from operations: ₹18,524.14 lakhs (vs ₹18,588.27 lakhs in Q2 FY2026) - virtually flat
Other income: ₹60.84 lakhs (vs ₹97.85 lakhs in Q2 FY2026)
Total expenses: ₹17,080.21 lakhs (vs ₹17,694.06 lakhs in Q2 FY2026)
Profit before tax: ₹1,504.77 lakhs (vs ₹992.06 lakhs in Q2 FY2026) - 51.7% increase
Tax expense: ₹383.46 lakhs (vs ₹230.81 lakhs in Q2 FY2026)
Profit after tax: ₹1,121.31 lakhs (vs ₹761.25 lakhs in Q2 FY2026) - 47.3% increase
Basic EPS: ₹1.12 (vs ₹0.76 in Q2 FY2026)
Diluted EPS: ₹1.12 (vs ₹0.76 in Q2 FY2026)

Revenue from operations: ₹37,905.18 lakhs (vs ₹37,236.21 lakhs in H1 FY2026) - 1.8% increase
Other income: ₹368.51 lakhs (vs ₹436.69 lakhs in H1 FY2026)
Profit before tax: ₹3,197.58 lakhs (vs ₹2,087.37 lakhs in H1 FY2026) - 53.2% increase
Profit after tax: ₹2,263.80 lakhs (vs ₹1,591.37 lakhs in H1 FY2026) - 42.3% increase
Basic EPS: ₹2.26 (vs ₹1.59 in H1 FY2026)
Diluted EPS: ₹2.26 (vs ₹1.59 in H1 FY2026)

Q2 FY2027 EBITDA: ₹1,755.13 lakhs with 9.47% margin
Q2 FY2026 EBITDA: ₹1,285.80 lakhs with 6.92% margin
Adjusted EBITDA (excluding forex gain/loss and other income): ₹1,873.67 lakhs with 10.11% margin in Q2 FY2027

Total assets: ₹55,366.04 lakhs (vs ₹55,736.79 lakhs as at 31st March 2026)
Inventories: ₹17,245.36 lakhs (increased from ₹14,775.50 lakhs)
Trade receivables: ₹18,978.01 lakhs (decreased from ₹23,863.28 lakhs)
Cash and cash equivalents: ₹939.93 lakhs (increased from ₹805.97 lakhs)
Total equity: ₹35,992.38 lakhs (increased from ₹35,222.24 lakhs)
Current borrowings: ₹1,947.58 lakhs (new borrowing during the period)

Cash generated from operations: ₹3,365.97 lakhs (vs negative ₹1,905.59 lakhs in H1 FY2026)
Net cash from operations: ₹2,668.23 lakhs (vs negative ₹2,679.96 lakhs in H1 FY2026)
Net cash used in investing activities: ₹2,982.52 lakhs (vs ₹3,507.82 lakhs generated in H1 FY2026)
Net cash from financing activities: ₹448.25 lakhs (vs negative ₹2,589.58 lakhs in H1 FY2026)
Net increase in cash: ₹133.96 lakhs (vs decrease of ₹1,761.72 lakhs in H1 FY2026)

The company paid dividends including tax thereon of ₹1,482.65 lakhs during H1 FY2027
This compares to ₹1,499.73 lakhs dividend payment in H1 FY2026

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors on 30th October, 2026

The company issued bonus shares in 1:1 ratio during the quarter ended September 30, 2025
All share and per share information reflects the effect of the bonus share issuance
The company has only one reportable segment: Bulk drug and Chemicals
The company does not have any subsidiary/associate/joint ventures as on 30th September 2026
Previous period figures have been regrouped and reclassified where necessary

Not Specified

Not Specified